The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | The prognostic value of peripheral blood MRD status following Elo-KRd in newly diagnosed myeloma
Benjamin Derman, MD, University of Chicago, Chicago, IL, explores the utility of next-generation sequencing (NGS) of peripheral blood (PB) samples as an alternative to bone marrow (BM) samples for assessing the measurable residual disease (MRD) status of patients with newly diagnosed multiple myeloma (MM) following 4 cycles of treatment with elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd). The study found that MRD status in both BM and PB is a prognostic indicator, predicting outcomes such as progression-free survival (PFS) and overall survival (OS). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Janssen, COTA Healthcare
Independent reviewer for a clinical trial: BMS
